ICU Medical, Inc.
NASDAQ•ICUI
CEO: Mr. Vivek Jain
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1992-03-31
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Contact Information
Market Cap
$3.10B
P/E (TTM)
4227.8
57.9
Dividend Yield
--
52W High
$160.29
52W Low
$107.00
52W Range
Rank37Top 34.1%
4.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$540.31M+0.00%
4-Quarter Trend
EPS
-$0.64+0.00%
4-Quarter Trend
FCF
$35.95M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Net Income Swings to Profit Net Income swung to $732K profit in 2025, a significant reversal from $(117.7)M net loss reported in 2024.
IV Solutions Business Divestiture Sold 60% JV stake in IV Solutions business, recording a $44.8M gain on sale during 2025.
Gross Margin Expansion Achieved Gross margin improved to 36.8% in 2025, driven by divestiture of lower margin IV Solutions business.
Debt Reduction Via Proceeds Utilized $200.0M from JV sale proceeds to pay down a portion of the outstanding Term Loan A debt.
Risk Factors
Trade Tariff Import Exposure Significant tariff risk remains on imports from Costa Rica and Mexico manufacturing facilities, potentially increasing costs substantially.
FDA Regulatory Warning Letter Received 2025 FDA Warning Letter regarding MedFusion and CADD pump modifications requiring new 510(k) clearance.
Supply Chain Cost Volatility Continued exposure to inflation, rising interest rates, and geopolitical disruptions impacting raw material costs and supply chains.
Smiths Medical Integration Risk Failure to fully complete complex integration of Smiths Medical acquisition may delay realization of anticipated synergies.
Outlook
2026 Capital Expenditure Estimate Estimate 2026 capital expenditures in the range of $85 million to $100 million USD, funded by cash.
Resolving FDA Warning Letter Actively working with the FDA to resolve all concerns cited in the 2025 Warning Letter in a timely manner.
R&D Investment Maintained R&D expenses slightly decreased to $87.5M in 2025, supporting ongoing product development and competitiveness.
Managing Long-Term Debt Monitoring liquidity position while managing $1.27B net long-term debt outstanding as of December 31, 2025.
Peer Comparison
Revenue (TTM)
$4.25B
$3.68B
$3.31B
Gross Margin (Latest Quarter)
92.8%
91.0%
85.1%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| LIVN | $3.40B | -14.0 | -21.5% | 18.2% |
| ICUI | $3.10B | 4227.8 | 0.0% | 34.4% |
| PBH | $2.93B | 15.7 | 10.2% | 30.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-3.7%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 6, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data